

# VG PARTNERS

---

## VG Partners ranks as one of world's top 100 VC Funds

Toronto, Ontario, August 20, 2009 – VG Partners is proud to be named as one of the world's top 100 venture capital funds in 2009 by Red Herring, a California-based publication covering innovation across many sectors including biosciences.



A premier Canadian private equity investment group, VG Partners is the only privately-held Canadian firm to make the list. As well, it is the only Ontario venture capital firm to be honoured.

The rankings resulted from Red Herring's eight months of research, over which it screened 1,000 firms worldwide on both a qualitative and quantitative basis.

[Read Red Herring Press Release](#)

"We are very excited to be named as one of the world's top 100 venture capital funds by Red Herring," said Dr. Luc Marengère, Managing General Partner at VG Partners. "It's a real honour to be one of *only* three Canadian firms to make the list."

"In the life sciences space, many of our investee companies have enjoyed enviable success. This includes forging strategic alliances with industry leaders such as Human Genome Sciences and Japan's Mitsubishi Tanabe Pharma," added Dr. Luc Marengère. The life sciences team is now capitalizing on its portfolio success by raising its second venture fund.

**Over the past 25 years, VG Partners has backed over 200 companies including:**

### Examples of current Portfolio Investee Companies

- **Aegera Oncology** is a clinical-stage biotechnology company that develops drugs to treat cancer and other serious diseases including pain related to diabetes and other injuries.
- **Cytochroma** is developing a number of vitamin D-based products for renal disease and other metabolic diseases.
- **Interface Biologics** develops unique biomaterials for the coating and manufacturing of a new generation of medical devices to improve compatibility, efficacy and safety.
- **VisualSonics** is leading the world in ultrasound imaging products for preclinical research, which it sells globally. Clinical applications are currently under development.

### Exited Companies

- **Kadmus Pharmaceutical** developed therapeutics for pain, obesity and other central nervous system disorders. In May 2007, its main program was acquired by Dutch biotech firm, Organon BioSciences N.V., now part of Schering-Plough.
- **Cita NeuroPharmaceuticals** was acquired by Vernalis PLC in December 2005. Cita developed and commercialized small molecule drug candidates for neurological diseases and disorders.

## **About VG Partners**

A premier Canadian private equity investment group, VG Partners builds innovative companies into global successes. Since 1982, we have invested over \$1.3 billion in more than 200 North American companies, working alongside business owners to maximize potential. Our investment team provides an unparalleled hands-on approach and a breadth of industry experience within technology, life sciences and mezzgrowth industrial and consumer sectors. VG Partners is part of VenGrowth Private Equity Partners. For more, visit [vgpartners.com](http://vgpartners.com)

## **Life Sciences Expertise**

Drawing on our technical and operational strengths, our highly experienced team works collaboratively with top tier entrepreneurs to build leading innovative companies developing products in the life sciences. As an established lead investor, we are committed to maximizing returns for all shareholders by investing locally and building globally competitive enterprises. Built on a foundation of relationships, our team has a proven ability to attract capital from Canada and the U.S. to support our life cycle investment strategy.

Media inquiries:

Tanya Gallus

Communications Specialist

416.628.9238

[tgallus@vengrowth.com](mailto:tgallus@vengrowth.com)